CA2122473A1 - Nuclear Matrix Protein Fluid Assay - Google Patents

Nuclear Matrix Protein Fluid Assay

Info

Publication number
CA2122473A1
CA2122473A1 CA 2122473 CA2122473A CA2122473A1 CA 2122473 A1 CA2122473 A1 CA 2122473A1 CA 2122473 CA2122473 CA 2122473 CA 2122473 A CA2122473 A CA 2122473A CA 2122473 A1 CA2122473 A1 CA 2122473A1
Authority
CA
Canada
Prior art keywords
nuclear matrix
matrix protein
fluid assay
protein fluid
evaluating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2122473
Other languages
French (fr)
Other versions
CA2122473C (en
Inventor
Lee Anne Beausang
Graham P. Lidgard
Thomas E. Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Matritech Inc
Original Assignee
Lee Anne Beausang
Graham P. Lidgard
Thomas E. Miller
Matritech, Inc.
Milano Acquisition Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lee Anne Beausang, Graham P. Lidgard, Thomas E. Miller, Matritech, Inc., Milano Acquisition Corp. filed Critical Lee Anne Beausang
Publication of CA2122473A1 publication Critical patent/CA2122473A1/en
Application granted granted Critical
Publication of CA2122473C publication Critical patent/CA2122473C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/961—Chemistry: molecular biology and microbiology including a step of forming, releasing, or exposing the antigen or forming the hapten-immunogenic carrier complex or the antigen per se

Abstract

Disclosed is a method for detecting and quantitating soluble nuclear matrix proteins in body fluids and extracellular media. The method is useful for monitoring the viability of cells and tissue, for evaluating the progress of a disease or its treatment, and for evaluating the cytotoxicity of unknown compounds. Also disclosed are methods for inducing the release of nuclear matrix proteins insoluble form from cells.
CA002122473A 1991-10-31 1992-10-29 Nuclear matrix protein fluid assay Expired - Lifetime CA2122473C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78580491A 1991-10-31 1991-10-31
US785,804 1991-10-31
PCT/US1992/009220 WO1993009437A2 (en) 1991-10-31 1992-10-29 Nuclear matrix protein fluid assay

Publications (2)

Publication Number Publication Date
CA2122473A1 true CA2122473A1 (en) 1993-05-13
CA2122473C CA2122473C (en) 2001-01-23

Family

ID=25136671

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002122473A Expired - Lifetime CA2122473C (en) 1991-10-31 1992-10-29 Nuclear matrix protein fluid assay

Country Status (9)

Country Link
US (8) US5965376A (en)
EP (1) EP0642668B1 (en)
JP (1) JP3190042B2 (en)
AT (1) ATE191567T1 (en)
AU (1) AU658257B2 (en)
CA (1) CA2122473C (en)
DE (1) DE69230890T2 (en)
ES (1) ES2147555T3 (en)
WO (1) WO1993009437A2 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE191567T1 (en) * 1991-10-31 2000-04-15 Matritech Inc DETERMINATION OF NUCLEAR MATRIX PROTEINS IN LIQUIDS
JPH07509602A (en) * 1992-06-22 1995-10-26 マトリテク　インコーポレイテッド Novel malignant cell type internal nuclear matrix marker
US5547928A (en) * 1993-12-17 1996-08-20 Matritech, Inc. Methods and compositions for the detection of colon cancers
US6280956B1 (en) 1995-11-03 2001-08-28 University Of Pittsburgh Antibodies to bladder cancer nuclear matrix proteins and their use
US5866535A (en) * 1995-11-03 1999-02-02 University Of Pittsburgh Bladder nuclear matrix proteins, polynucleotide sequences encoding them, and their use
US5914238A (en) * 1996-06-05 1999-06-22 Matritech, Inc. Materials and methods for detection of breast cancer
US5858683A (en) * 1996-08-30 1999-01-12 Matritech, Inc. Methods and compositions for the detection of cervical cancer
US6232443B1 (en) 1997-04-08 2001-05-15 University Of Pittsburgh Renal nuclear matrix proteins, polynucleotide sequences encoding them, and their use
ES2265682T3 (en) 1998-03-18 2007-02-16 Roche Diagnostics Gmbh DETECTION OF APOPTOTIC PRODUCTS.
US7229772B1 (en) 1998-03-18 2007-06-12 Roche Diagnostics Gmbh Detection of apoptotic products
DE60035499T2 (en) 1999-05-17 2008-03-20 Cytyc Corp., Marlborough IDENTIFICATION OF MATERIAL FROM THE MILK CHANNEL OF CHEST
US6617432B1 (en) * 1999-10-15 2003-09-09 University Of Pittsburgh Nuclear matrix proteins polynucleotide sequences encoding them and their use
US20030228640A1 (en) * 1999-10-15 2003-12-11 University Of Pittsburgh Nuclear matrix proteins, polynucleotide sequences encoding them, and their use
KR100350111B1 (en) 2000-02-22 2002-08-23 삼성전자 주식회사 Wiring of Semiconductor Device and Method for Manufacturing Thereof
US7654227B1 (en) * 2001-12-20 2010-02-02 Pat Yananton Absorbent pad for entrapping small and large particles, retaining liquids and eliminating odors
US7080373B2 (en) * 2001-03-07 2006-07-18 Freescale Semiconductor, Inc. Method and device for creating and using pre-internalized program files
US20030044352A1 (en) * 2001-04-24 2003-03-06 Phillips Nigel C. Method for evaluating the efficacy of treatment with bacterial DNA and bacterial cell walls
US7193065B2 (en) * 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
US20040018973A1 (en) * 2002-01-25 2004-01-29 University Of Pittsburgh Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof
JP4274856B2 (en) * 2003-06-19 2009-06-10 オリンパス株式会社 Method for detecting reaction between DNA and DNA-binding protein
EP1668854A1 (en) * 2003-09-23 2006-06-14 Koninklijke Philips Electronics N.V. Adaptive filter
US7649988B2 (en) 2004-06-15 2010-01-19 Acoustic Technologies, Inc. Comfort noise generator using modified Doblinger noise estimate
US7846676B2 (en) * 2004-07-19 2010-12-07 Cell Biosciences, Inc. Methods and devices for analyte detection
WO2006014680A1 (en) * 2004-07-19 2006-02-09 Cell Biosciences, Inc. Methods and devices for analyte detection
US7935479B2 (en) * 2004-07-19 2011-05-03 Cell Biosciences, Inc. Methods and devices for analyte detection
JP2008536128A (en) * 2005-04-09 2008-09-04 セル バイオサイエンシズ，インコーポレイテッド Automated microvolume assay system
ES2429564T3 (en) 2005-05-18 2013-11-15 Novartis Ag Procedures for the diagnosis and treatment of diseases that have an autoimmune and / or inflammatory component
US20070015166A1 (en) * 2005-07-14 2007-01-18 Nilsen Thor W Lateral flow methods and devices for detection of nucleic acid binding proteins
US8945361B2 (en) 2005-09-20 2015-02-03 ProteinSimple Electrophoresis standards, methods and kits
US20080017512A1 (en) * 2006-07-24 2008-01-24 Bordunov Andrei V Coatings for capillaries capable of capturing analytes
WO2008057605A2 (en) * 2006-11-10 2008-05-15 Quidel Corporation Nuclear protein extraction medium and method of use
US20090023156A1 (en) * 2007-07-20 2009-01-22 Voss Karl O Methods and reagents for quantifying analytes
US10107782B2 (en) 2008-01-25 2018-10-23 ProteinSimple Method to perform limited two dimensional separation of proteins and other biologicals
JP2011206049A (en) 2010-03-08 2011-10-20 Sumio Sugano Necrosis marker and use thereof
EP2839276B1 (en) 2012-04-19 2018-06-27 ProteinSimple Dual wavelength isoelectric focusing for determining drug load in antibody drug conjugates
US9766206B2 (en) 2013-09-27 2017-09-19 ProteinSimple Apparatus, systems, and methods for capillary electrophoresis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4628027A (en) * 1982-05-19 1986-12-09 Molecular Engineering Associates, Ltd. Vitro diagnostic methods using monoclonal antibodies against connective tissue proteins
US5273877A (en) * 1985-12-24 1993-12-28 Massachusetts Institute Of Technology Non-histological cell type determination
US4882268A (en) * 1985-12-24 1989-11-21 Massachusetts Institute Of Technology Method for determining tissue of origin and degree of malignancy of tumor cells
US5032508A (en) * 1988-09-08 1991-07-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US4861581A (en) * 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US4937185A (en) * 1987-07-31 1990-06-26 The Ohio State University Research Foundation Detection of circulating antibodies to a cancer marker protein
WO1989006697A1 (en) * 1988-01-19 1989-07-27 The University Of Sydney Detection of cell death
US5017474A (en) * 1988-02-12 1991-05-21 Eastman Kodak Company Wash solution, test kit and method for the determination of an immunological ligand
US5098890A (en) * 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
WO1991017266A1 (en) * 1990-05-01 1991-11-14 Isis Pharmaceuticals, Inc. Identification of novel drugs and reagents
ATE191567T1 (en) * 1991-10-31 2000-04-15 Matritech Inc DETERMINATION OF NUCLEAR MATRIX PROTEINS IN LIQUIDS
WO1993009142A1 (en) * 1991-11-08 1993-05-13 University Of Saskatchewan Acute phase proteins for detection and prognosis of infection and tissue damage
WO1993021531A1 (en) * 1992-04-15 1993-10-28 Brigham And Women's Hospital, Inc. Method and composition for the detection of lesions
JPH07509602A (en) * 1992-06-22 1995-10-26 マトリテク　インコーポレイテッド Novel malignant cell type internal nuclear matrix marker

Also Published As

Publication number Publication date
AU3123593A (en) 1993-06-07
AU658257B2 (en) 1995-04-06
EP0642668A1 (en) 1995-03-15
US5965376A (en) 1999-10-12
US6740494B2 (en) 2004-05-25
US20060127941A1 (en) 2006-06-15
JPH07500671A (en) 1995-01-19
JP3190042B2 (en) 2001-07-16
EP0642668B1 (en) 2000-04-05
US20030096304A1 (en) 2003-05-22
WO1993009437A2 (en) 1993-05-13
US6410247B1 (en) 2002-06-25
US5989826A (en) 1999-11-23
ES2147555T3 (en) 2000-09-16
DE69230890T2 (en) 2000-12-07
ATE191567T1 (en) 2000-04-15
US20050059026A1 (en) 2005-03-17
WO1993009437A3 (en) 1993-06-10
CA2122473C (en) 2001-01-23
US5840503A (en) 1998-11-24
US6162608A (en) 2000-12-19
DE69230890D1 (en) 2000-05-11

Similar Documents

Publication Publication Date Title
CA2122473A1 (en) Nuclear Matrix Protein Fluid Assay
ATE205602T1 (en) METHOD AND DEVICE FOR DETECTING AND QUANTIFYING GLUCOSE IN BODY FLUID
WO1998053076A3 (en) Compounds for diagnosis of tuberculosis and methods for their use
EP0413678A3 (en) Method for the detection and determination of human serum albumin in biological fluids using fluorogenic cyanine dyes
CA2203885A1 (en) Treating red blood cell solutions with anti-viral agents
GR3034647T3 (en) Test article and method for performing blood coagulation assays.
ES2133813T3 (en) LAMININE CHAINS: DIAGNOSIS AND THERAPEUTIC USE.
WO1998016645A3 (en) Compounds and methods for diagnosis of tuberculosis
AU3575089A (en) Method of detecting bacteria in urine
AU8423991A (en) Biological fluid specimen collection bag
NO903988D0 (en) DEVICE AND PROCEDURE FOR EVALUATING A BODY'S ABILITY TO EXPLORE A PRODUCT AND ITS APPLICATION ON A STONE TEST.
CA2070647A1 (en) Use of an anticoagulant as a diagnostic agent
HU906639D0 (en) Diagnostic process for detecting htlv-i peptides and their antibodies causing infection, and vaccine for treating the disease
DE69428278D1 (en) LEUKOZYTADHAESION TEST
NO177463C (en) STLV-III Related Polypeptides, Diagnostic Test Kits, and In Vitro Assay Procedure for Detecting Anti-HIV-2 Antibodies in Body Fluid Test
WO2001044438A3 (en) Serological diagnostic method with rickettsia pulicis bacterium
CA2172243A1 (en) Method for quantifying bpi in body fluids
Baptista et al. Plastination of the wrist: Potential uses in education and clinical medicine
AU4294089A (en) Process for the detection of legionella antigens in body fluids and the like, as well as a test kit for performing the process
ES8700440A1 (en) Diagnostic kit for detecting amines and its production, and a method for detecting amines.
CA2050941A1 (en) Antibody to smooth muscle myosin heavy chains
SU1304398A1 (en) Serovar strain vibrio nag 62 for preparing diagnosis serum against serovar 62 vibrions
DE69013823T2 (en) Hydraulic sensor for the detection and localization of quenching in superconductors.
DE60029939D1 (en) DIAGNOSIS PROCEDURE FOR WHIPPLES DISEASE
SU1304399A1 (en) Serovar strain vibrio nag 60 for preparing diagnosis serum against serovar 60 vibrions

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry